Labo Euromedis (FRA:61R) NonCurrent Deferred Liabilities: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:61R Labo Euromedis FRA:61R
55 GF Score
Price €4.90
GF Value €4.25
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Labo Euromedis NonCurrent Deferred Liabilities?

Labo Euromedis FRA:61R +0.41% 55 NonCurrent Deferred Liabilities is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:61R with a GF Score™ of 55/100 and a GF Value™ of €4.25 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Labo Euromedis's non-current deferred liabilities for the quarter that ended in Dec. 2025 was €0.00 Mil.

Labo Euromedis NonCurrent Deferred Liabilities Related Terms

Labo Euromedis NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Labo Euromedis's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labo Euromedis NonCurrent Deferred Liabilities Chart

Labo Euromedis Annual Data
Trend Jul15 Jul16 Jul17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Labo Euromedis Semi-Annual Data
Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:61R
55GF Score
Labo Euromedis FRA:61R
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0.00 Mil mean?
Labo Euromedis (FRA:61R) has a NonCurrent Deferred Liabilities of €0.00 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Labo Euromedis and its competitors.
Is Labo Euromedis' NonCurrent Deferred Liabilities too high?
Labo Euromedis' current NonCurrent Deferred Liabilities is €0.00 Mil. Overall, Labo Euromedis has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' NonCurrent Deferred Liabilities compare to MCK and CAH?
Labo Euromedis' NonCurrent Deferred Liabilities of €0.00 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Distribution company?
A good NonCurrent Deferred Liabilities depends on the Medical Distribution industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Labo Euromedis and its competitors. Labo Euromedis's current NonCurrent Deferred Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Based on GuruFocus' analysis, Labo Euromedis (FRA:61R) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.25, compared to a current price of €4.90 — trading 15.3% above its estimated fair value. The current NonCurrent Deferred Liabilities is €0.00 Mil. Labo Euromedis' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current NonCurrent Deferred Liabilities is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Labo Euromedis (FRA:61R) Overvalued in 2026?

Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued. The current stock price of €4.90 is trading 15.3% above its estimated GF Value™ of €4.25. GuruFocus considers Labo Euromedis to be Modestly Overvalued.

Key valuation signals for FRA:61R:

  • NonCurrent Deferred Liabilities: €0.00 Mil
  • GF Value™: €4.25 vs. price of €4.90 (15.3% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Labo Euromedis Business Description

Address ZI de la Tuilerie, Neuilly-sous-Clermont, FRA, 60290
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
55GF Score

Get the complete analysis for FRA:61R

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.90
Price
€4.25
GF Value